0.02Open0.05Pre Close34 Volume137 Open Interest8.00Strike Price83.00Turnover112.29%IV23.85%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0578Delta0.0615Gamma208.80Leverage Ratio-0.0111Theta-0.0002Rho-12.08Eff Leverage0.0019Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet